Hikma files for generic ZYTIGA® approval

London, 5 August 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces that it has filed an Abbreviated New Drug Application (“ANDA”) with the U.S. Food and Drug Administration (FDA) seeking approval to market abiraterone acetate tablets, 250 mg. Hikma’s ANDA product is a generic version of Janssen Biotech’s ZYTIGA®, which is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Press Release Product 5 August 2015

BTG International Limited, Janssen Biotech, and various other Janssen affiliates filed a patent infringement suit on 31 July 2015 in the U.S. District Court for the District of New Jersey seeking to prevent Hikma from commercialising its ANDA product prior to the expiration of U.S. Patent No. 8,822,438. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Hikma’s ANDA until 28 October2018.

Based on available information, Hikma believes it may be a “first applicant” to file an ANDA for the generic version of ZYTIGA® and, should its ANDA be approved, may be entitled to 180 days of generic marketing exclusivity.

For the twelve-month period ending June 2015, ZYTIGA® achieved U.S. sales of approximately $1.1 billion according to IMS Health Data.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.